ACR 2022 Tweet by Eric Dein

Ab2126 #ACR22 Risankizumab on Enthesitis/Dactylitis
KEEPsAKE 1&2 - RZB v PBO
1407 pts -baseline 63% enth, 28% dact, 20% both
Wk 24: 14% decr. enthesitis, 17% decr dact, 13% decr both
Mean time to resolution decreased
Results maintained through wk 52
@RheumNow